Last reviewed · How we verify
NCT06875193: KLIMT
DM Treatment to Evaluate the Efficacy and Safety of Dapagliflozin or Pioglitazone in Patients with Type 2 Diabetes
Phase 4 trial testing DW6012(Dasidiem tab. 10/100mg) in Type2diabetes in 196 participants. Currently enrolling.
31 December 2025
Quick facts
| Lead sponsor | Dong Wha Pharmaceutical Co. Ltd. |
|---|---|
| Phase | Phase 4 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | supportive care |
| Enrollment | 196 |
| Start date | 28 May 2024 |
| Primary completion | 31 December 2025 |
| Estimated completion | 31 December 2025 |
| Sites | 1 location across South Korea |
Drugs / interventions tested
- DW6012(Dasidiem tab. 10/100mg) — full drug profile →
Conditions studied
- Type2diabetes — all drugs for Type2diabetes →
Sponsor
Dong Wha Pharmaceutical Co. Ltd. — full company profile →
Who can join
19 and older, any sex, with Type2diabetes. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Key finding of DM Treatment with combination, A MuLticenter, Randomized, Parallel, Gathering Information of phase 4 Trial to Evaluate the Efficacy and Safety of Dapagliflozin or Pioglitazone add-on to Metformin and DPP-4 inhibitor in Patients with Type 2 Diabetes Who Have Inadequate Glycaemic Control on a Background Combination of Metformin and DPP-4 inhibitor(KLIMT Study)
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06875193
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Type2diabetes
Currently open trials in the same condition.
- NCT06345196 — Motivational Interviewing Applied to Individuals With Diabetes · NA · recruiting
- NCT06322212 — Type 2 Diabetes and Blood Brain Barrier Improvement · EARLY_PHASE1 · recruiting
- NCT06575478 — Evaluation of Fuling Yunhua Granules and Dihuang Baoyuan Granules in Drug Naive Type 2 Diabetes Patients · Phase 2 · recruiting
- NCT06469437 — The Impact of Geriatric Assessment on the Treatment Plan of Elderly Patients With T2DM · NA · recruiting
- NCT06267391 — Safety and Effectiveness of Endoscopic Intestinal Re-Cellularization Therapy in Individuals With Type II Diabetes · NA · recruiting
Other Dong Wha Pharmaceutical Co. Ltd. trials
Trials by the same sponsor.
- NCT05823870 — This Study is to Compare and Evaluate the Safety and Pharmacokinetic Characteristics (PK) After Administration of DW6014 · Phase 1 · completed
- NCT05874180 — A Pharmacokinetic Study of DW6013 (FDC of Linagliptin and Metformin) in Healthy Adult Volunteers in Fed Condition · Phase 1 · completed
- NCT05874167 — A Pharmacokinetic Study of DW6013 (FDC of Linagliptin and Metformin) in Healthy Adult Volunteers · Phase 1 · completed
- NCT05403281 — A Pharmacokinetic Study of DW6012 (FDC of Dapagliflozin and Sitagliptin) in Healthy Adult Volunteers · Phase 1 · completed
- NCT07489183 — A Prospective, Open, Observational Study to Confirm the Lipid-lowering Effect, Changes in Glucose Metabolism, and Safety · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06875193 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Dong Wha Pharmaceutical Co. Ltd.
- Last refreshed: 17 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06875193.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing